Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. MXCT
MXCT logo

MXCT Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy MaxCyte Inc (MXCT) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
1.290
1 Day change
1.57%
52 Week Range
2.370
Analysis Updated At
2026/07/03
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

MXCT is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock lacks a strong technical breakout, has no recent news catalyst, no supportive proprietary buy signal, and the options setup is bearish-to-neutral with elevated implied volatility. I would not buy it now; the better call is to wait or avoid.

Technical Analysis

The chart is neutral to slightly weak. MACD histogram is below zero and negatively expanding, which points to fading momentum. RSI_6 at 52.27 is neutral and does not show oversold strength. Moving averages are converging, suggesting indecision rather than a confirmed uptrend. Price at 1.2175 sits just below the pivot at 1.239, with nearby support at 1.155 and resistance at 1.323. The short-term pattern expectation also leans weak, with a 60% chance of -0.51% next day and -3.23% next month.

Options Data

Bearish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

The options data is cautious. The put-call open interest ratio of 1.79 shows more puts than calls, which leans bearish. Option volume is zero, so there is no strong fresh directional flow today. Implied volatility is extremely high at 795.09 with IV rank 78.16 and IV percentile 97.62, indicating expensive options and heightened uncertainty rather than a clean bullish setup.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
2
Buy
8

Positive Catalysts

  • No news in the recent week, so there are no clear event-driven catalysts. Post-market was slightly positive at +0.21%, but that is minor. There is also no recent insider or hedge fund accumulation signal, and no recent congress trading data to suggest influential buying interest.

Neutral/Negative Catalysts

  • No recent news catalyst, no AI Stock Picker signal, and no SwingMax buy signal. Hedge funds are neutral and insiders are neutral, so there is no visible conviction from smart money. The options market leans bearish with a 1.79 put-call open interest ratio, while the stock’s technicals remain uninspiring and short-term probability tilts negative.

Financial Performance

No usable financial snapshot was provided, so the latest quarter cannot be assessed from the data available. Based on the input, there is no recent quarter season or growth trend information to support a buy decision.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target trend data was provided, so there is no evidence here of improving Wall Street sentiment. Overall, the Wall Street pros view appears mixed-to-negative by default because there is no visible upward revision trend, no fresh catalyst, and no supportive trading signal.

Wall Street analysts forecast MXCT stock price to rise
5 Analyst Rating
Wall Street analysts forecast MXCT stock price to rise
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.270
sliders
Low
4.94
Averages
6.92
High
8.89
Current: 1.270
sliders
Low
4.94
Averages
6.92
High
8.89
Craig-Hallum
Buy
downgrade
$7 -> $5
AI Analysis
2026-03-25
Reason
Craig-Hallum
Price Target
$7 -> $5
AI Analysis
2026-03-25
downgrade
Buy
Reason
Craig-Hallum lowered the firm's price target on MaxCyte to $5 from $7 and keeps a Buy rating on the shares. The firm notes the company reported an ostensibly weak quarter. However, Craig-Hallum points out that the company continues to make solid progress and that its fundamentals remain strong. In addition to supporting more late-stage programs than ever and launching a new product designed to build the early-stage customer pipeline, the firm believes that with the stock currently trading at a 50% discount to cash per share, the risk-to-reward profile is attractive.
BTIG
BTIG
Buy
to
Neutral
downgrade
2025-08-11
Reason
BTIG
BTIG
Price Target
2025-08-11
downgrade
Buy
to
Neutral
Reason
BTIG downgraded MaxCyte to Neutral from Buy without a price target after \"a tough Q2 business update\" and lowering of the bar for 2025. MaxCyte lowered its 2025 revenue guide by $5M, or 14% of its business, citing ongoing challenges for many of its cell and gene therapy customers to obtain capital to fund programs, purchase capital, or lease its systems, the analyst noted. The firm thinks the company still has a best-in-class electroporation platform, arguing that the \"number one driver to turn the business around is simply its customers becoming more readily able to raise money and invest in more programs.\"
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for MXCT
Unlock Now

People Also Watch